The role of TET2 in solid tumors and its therapeutic potential: a comprehensive review

Area of Science:

• Molecular Biology
• Cancer Research
• Epigenetics

Background:

• Tumors represent a major global health challenge, necessitating a deep understanding of their development mechanisms.
• Epigenetics, particularly DNA methylation, significantly influences gene expression and plays a critical role in tumorigenesis.
• Ten-eleven translocation 2 (TET2) is a key protein in DNA methylation modification, primarily recognized for its tumor-suppressive functions in hematological malignancies.

Purpose of the Study:

• To investigate the role and regulatory mechanisms of Ten-eleven translocation 2 (TET2) in solid tumors.
• To highlight the underappreciated involvement of TET2 in solid tumor development compared to its known role in hematological diseases.
• To explore the potential of TET2 as a clinical target for novel targeted therapies in malignant solid tumors.

Main Methods:

• Analysis of DNA methylation patterns associated with TET2.
• Investigation of TET2's regulatory functions in the context of solid tumor development.
• Review of existing literature on TET2 in hematological diseases and its potential implications for solid tumors.

Main Results:

• DNA methylation is a crucial epigenetic mechanism in tumor development, with TET2 playing a significant regulatory role.
• While TET2's function in hematological diseases is well-documented, its role in solid tumors remains largely unexplored.
• Understanding TET2's mechanisms in solid tumors is essential for advancing cancer research and therapeutic strategies.

Conclusions:

• Epigenetic modifications, including DNA methylation regulated by TET2, are fundamental to tumor development.
• Further research into TET2's function in solid tumors is warranted to uncover its potential as a therapeutic target.
• Investigating TET2 in solid tumors could pave the way for new clinical treatments for malignant tumors.